ロード中...
1963. PrEP Significantly Reduces the Rate of New HIV Diagnoses in US Metropolitan Statistical Areas Independent of Treatment as Prevention (2012–2017)
BACKGROUND: Tenofovir/Emtricitabine (TVD) was approved for a Pre-exposure Prophylaxis (PrEP) indication in the United States in July 2012. Biomedical HIV prevention tools can impact the rate of new HIV diagnoses but their relative contributions have not been described. METHODS: The analysis utilized...
保存先:
| 出版年: | Open Forum Infect Dis |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2019
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6808906/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz359.140 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|